We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

113 hedge funds and large institutions have $585M invested in Insys Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $9.01M | Put options by funds: $4.63M

29% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 21

15% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 34

8% more capital invested

Capital invested by funds: $539M → $585M (+$45.8M)

2% more funds holding

Funds holding: 111 → 113 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
113
Holders Change
+2
Holders Change %
+1.8%
% of All Funds
3.01%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
27
Increased
39
Reduced
34
Closed
21
Calls
$9.01M
Puts
$4.63M
Net Calls
+$4.38M
Net Calls Change
+$4.37M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$20.1M
2
JHIU
Janus Henderson Investors US
Colorado
+$11.3M
3
FCM
Frontier Capital Management
Massachusetts
+$9.31M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.11M
5
Morgan Stanley
Morgan Stanley
New York
+$9.06M

Top Sellers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
-$22.1M
2
BTP
Bloom Tree Partners
New York
-$20.7M
3
Tiger Global Management
Tiger Global Management
New York
-$11.6M
4
FAM
Foundation Asset Management
New York
-$9.12M
5
Millennium Management
Millennium Management
New York
-$5.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
26
Ghost Tree Capital
New York
$4.22M +$3.95M +200,000 New
QI
27
QS Investors
New York
$3.97M +$3.72M +188,236 New
GC
28
Guggenheim Capital
Illinois
$3.86M +$204K +10,312 +6%
JGC
29
J. Goldman & Co
New York
$3.48M +$336K +17,000 +11%
PI
30
Putnam Investments
Massachusetts
$3.11M -$74.3K -3,758 -2%
ACM
31
Argent Capital Management
Missouri
$3.04M +$32.6K +1,650 +1%
ARTA
32
A.R.T. Advisors
New York
$2.92M +$1.05M +53,200 +62%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$2.74M +$300K +15,162 +13%
Goldman Sachs
34
Goldman Sachs
New York
$2.69M -$4.19M -212,144 -62%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$2.67M +$407K +20,582 +19%
Deutsche Bank
36
Deutsche Bank
Germany
$2.5M +$1.6M +80,848 +214%
CS
37
Credit Suisse
Switzerland
$2.23M -$920K -46,524 -31%
AI
38
Analytic Investors
California
$2.11M +$588K +29,714 +42%
SAM
39
Shell Asset Management
Netherlands
$2.1M +$1.97M +99,412 New
WMSA
40
Weiss Multi-Strategy Advisers
New York
$1.85M +$356K +18,000 +26%
GH
41
GAM Holding
Switzerland
$1.77M – – –
DC
42
Deere & Company
Illinois
$1.76M +$1.65M +83,402 New
TCIM
43
TIAA CREF Investment Management
New York
$1.51M -$37.6K -1,900 -3%
CCI
44
Columbus Circle Investors
$1.46M +$1.37M +69,232 New
AQR Capital Management
45
AQR Capital Management
Connecticut
$1.32M -$328K -16,600 -21%
DCM
46
Dupont Capital Management
Delaware
$1.22M – – –
BIM
47
BlackRock Investment Management
Delaware
$1.22M -$5.7K -288 -0.5%
Bank of Montreal
48
Bank of Montreal
Ontario, Canada
$1.2M +$235K +11,870 +26%
American Century Companies
49
American Century Companies
Missouri
$1.17M -$2.99M -151,184 -73%
JWS
50
Juncture Wealth Strategies
Arizona
$1.1M +$1.04M +52,504 New
1
2
3 4 5

INSY Hedge Fund Activity: Q4 2014 in Review

113 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2014, worth a combined $585M — up 8.5% from $539M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new INSY positions and 21 closed out — a net gain of 6 holders — while 39 added to existing stakes and 34 trimmed.

The largest buyer was OrbiMed, adding an estimated $20.1M. The largest seller was Empyrean Capital Partners, cutting an estimated $22.1M.

  • 113 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2014, up from 111 in Q3 2014.
  • Funds reported $585M of Insys Therapeutics, Inc. stock for Q4 2014, up 8.5% quarter-over-quarter.
  • 27 funds opened new Insys Therapeutics, Inc. positions in Q4 2014 and 21 closed out, a net change of +6 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q4 2014 was OrbiMed, an estimated $20.1M added.
  • The largest Insys Therapeutics, Inc. seller in Q4 2014 was Empyrean Capital Partners, an estimated $22.1M sold.

Based on aggregated 13F filings for Q4 2014.